There was a time when President Trump could mention drug pricing controls and move markets. Now, not so much.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
The long-awaited robotic surgery system is designed to open up the market.
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.